Evelo Biosciences, Inc. (EVLO) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to Avalo Biosciences conference call. Discussed is third quarter 2021 business highlights. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's quest. At this time, I would like to turn the call over to Kendra Sweeney of Avalo. Please proceed. Thank you. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.ivelobio.com under the Investors tab. Today on our call, Simba Gill, Chief Executive Officer, Mark Bodmer, President of R&D and Chief Scientific Officer, and Jonathan Zung, Chief Development Officer, will review our recent business highlights and third quarter 2021 financial results. Before I begin, I would like to remind everyone that statements made during this conference call that do not relate to matters of historical fact, including statements about our objectives and anticipated clinical milestones, the impact of any of our product candidates, and the timing and results of any clinical studies should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual results could differ materially from those indicated by the forward-looking statements due to their impact of many factors. Participants are directed to the risk factors set forth in Avello's quarterly report on Form 10-Q for the quarter ended September 30, 2021, and the company's other filings with the Securities and Exchange Commission. Any forward-looking statements made today speak on...